

S1 Table. Current search strategy (COVID-NMA)

PubMed	(2019 nCoV[tiab] OR 2019nCoV[tiab] OR corona virus[tiab] OR corona viruses[tiab] OR coronavirus[tiab] OR coronaviruses[tiab] OR COVID[tiab] OR COVID19[tiab] OR nCov 2019[tiab] OR SARSCoV2[tiab] OR SARS CoV-2[tiab] OR SARSCoV2[tiab] OR SARSCoV-2[tiab] OR "COVID-19"[Mesh] OR "COVID-19 Testing"[Mesh] OR "COVID-19 Vaccines"[Mesh] OR "Coronavirus"[Mesh:NoExp] OR "SARS-CoV-2"[Mesh] OR "COVID-19"[nm] OR "COVID-19 drug treatment"[nm] OR "COVID-19 diagnostic testing"[nm] OR "COVID-19 serotherapy"[nm] OR "COVID-19 vaccine"[nm] OR "LAMP assay"[nm] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "spike protein, SARSCoV-2"[nm]) NOT ("animals"[mh] NOT "humans"[mh]) NOT (editorial[pt] OR newspaper article[pt])
Embase.com	(((('coronaviridae'/de OR 'coronavirinae'/de OR 'coronaviridae infection'/de OR 'coronavirus disease 2019'/exp OR 'coronavirus infection'/de OR 'SARS-related coronavirus'/de OR 'Severe acute respiratory syndrome coronavirus 2'/exp OR '2019 nCoV':ti,ab,kw OR 2019nCoV:ti,ab,kw OR ((corona* OR corono*) NEAR/1 (virus* OR viral* OR virinae*)):ti,ab,kw OR coronavir*:ti,ab,kw OR coronovir*:ti,ab,kw OR COVID:ti,ab,kw OR COVID19:ti,ab,kw OR HCoV*:ti,ab,kw OR 'nCov 2019':ti,ab,kw OR 'SARS CoV2':ti,ab,kw OR 'SARS CoV 2':ti,ab,kw OR SARSCoV2:ti,ab,kw OR 'SARSCoV 2':ti,ab,kw) NOT (('animal experiment'/de OR 'animal'/exp) NOT ('human'/exp OR 'human experiment'/de))) NOT 'editorial'/it) NOT ([medline]/lim OR [pubmed-not-medline]/lim) AND [1-12-2019]/sd
CENTRAL	("2019 nCoV" OR 2019nCoV OR "corona virus*" OR coronavirus* OR COVID OR COVID19 OR "nCov 2019" OR "SARS-CoV2" OR "SARS CoV-2" OR SARSCoV2 OR "SARSCoV-2"):TI,AB AND CENTRAL:TARGET 2 Coronavirus:MH AND CENTRAL:TARGET 3 Coronavirus:EH AND CENTRAL:TARGET 4 #1 OR #2 OR #3 5 2019 TO 2021:YR AND CENTRAL:TARGET 6 #5 AND #4 7 INSEGMENT 8 #6 NOT #7

S2 Table. Completeness of reporting of CONSORT sub-items (N=244)

CONSORT Section	Checklist item	Reported N (%)
Section 6a		
Clear primary outcome	Was the primary outcome(s) clearly identified (e.g., the primary/main outcome was pain)?	219 (90%)
Variable of interest	The variable of interest (e.g., pain, all-cause mortality)	216 (89%)
How the outcome was assessed	How the outcome was assessed (e.g., VAS, Beck Depression Inventory score, pain scale)	189 (77%)
The analysis metric	The analysis metric (e.g., change from baseline, final value, time to event)	214 (88%)
The summary measure for each study group	The summary measure for each study group (e.g., mean, proportion with score > 2)	183 (75%)
Time point of interest for analysis	Time point of interest for analysis (e.g., 3 months)*NA if <i>survival analysis</i>	195 (80%)
Who assessed the outcome	Who assessed the outcome (e.g., the patient, doctor, nurse, caregiver, other)	94 (39%)
Section 8a and 9		
Method of sequence generation	Method used to generate the random allocation sequence	201 (82%)
Mechanism allocation concealment	Mechanism used to implement the random allocation sequence (e.g., sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	139 (57%)
Section 11b (N=107)		
Who was blinded	Was the study blinded?	74 (69%)
How the blinding was performed	Who (i.e., participants, healthcare providers, data collectors, outcome adjudicators, and data analysts) was blinded to treatment assignments?	87 (81%)
Similarities of the characteristics of the interventions	How was the blinding performed? (e.g., used of placebo, intervention by physician unaware of the study)	49 (46%)

S2 Table. (continued).

CONSORT Section	Checklist item	Reported N (%)
Section 13b		
Flow chart	Did the authors report a flow chart	204 (84%)
Participants randomized	Number of participants randomized in each group	233 (95%)
Participants who received treatment	Number of participants who received intended treatment in each group	204 (84%)
Participants lost to follow-up	Number of participants lost to follow-up with reasons in each group	236 (97%)
Participants who discontinued intervention	Number of participants who discontinued intervention with reasons in each group	150 (61%)
Participants analyzed	Number of participants analyzed for the primary outcome in each group	235 (96%)
Section 17a		
Result*	Result in each group (mean (SD) or number of events/N)	223 (91%)
Difference in estimated effect	Difference in estimated effect between groups (e.g., odds ratio (OR), risk ratio (RR), risk difference (RD), hazard ratio (HR), difference in median survival time, mean difference (MD))	126 (52%)
Precision	Precision for difference between groups (e.g., 95% CI)	125 (51%)
Section 19		
List of harms addressed	How harms-related information was collected (List of harm related events that were addressed)	132 (54%)
Mode of data collection	Mode of data collection (Full description of methods used to collect the harm related information)	110 (45%)
Time frame of surveillance	Timing (description of time frame of surveillance)	118 (48%)
Person responsible making attribution	Attribution methods (Person responsible making attribution disclosed and whether blinding was used)	94 (39%)
Participant withdrawals due to harm*	For each group, participant withdrawals due to harm	96 (39%)
Results of each harm type*	Results in each group for each harms type with denominator (mean [SD] or number of events/N)	189 (77%)
Section 23		
Registration number	The registration number	223 (91%)

* One trial not assessed, since only baseline data were presented. None of the pre-specified outcomes presented in the result section.

S3 Table. Changes in CONSORT items between preprint and peer-reviewed journal publication (n=76)

Consort section	Completely reported, not changed	Partially reported, not changed	Not reported, not changed	Changed to completely reported from partial	Changed to completely reported from not reported	Changed to partially reported from not reported	Changed to partially reported from complete	Changed to not reported from complete	Changed to not reported from partial
Outcome	26 (34%)	38 (50%)	3 (4%)	4 (5%)	0 (0%)	2 (3%)	0 (0%)	1 (1%)	2 (3%)
Sequence generation	69 (91%)	-	4 (5%)	-	3 (4%)	-	-	0 (0%)	-
Allocation concealment	49 (64%)	-	20 (26%)	-	6 (8%)	-	-	1 (1%)	-
Blinding*	15 (20%)	12 (16%)	1 (1%)	6 (8%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
Participant flow	43 (57%)	27 (36%)	0 (0%)	5 (7%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
Outcomes and estimation	47 (62%)	22 (29%)	2 (3%)	3 (4%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)
Harms	5 (7%)	59 (78%)	2 (3%)	6 (8%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	3 (4%)
Registration	73 (96%)	-	0 (0%)	-	3 (4%)	-	-	0 (0%)	-
Overall	4 (5%)	70 (92%)	0 (0%)	2 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Percentages may not add up to 100% due to rounding.

*41 trials were unblinded